Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable safety profile.
作者信息
Richardson Paul, Htut Myo, Scott Emma, Prada Claudia Paba, Gupta Ira
机构信息
Dana-Farber Cancer Institute, Boston, MA.
City of Hope, Duarte, CA.
出版信息
Haematologica. 2025 Feb 1;110(2):488-492. doi: 10.3324/haematol.2024.285380.
Abstract
摘要
相似文献
1
Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable safety profile.在复发和/或难治性多发性骨髓瘤中，他拉唑帕吉与泊马度胺和地塞米松联合使用显示出令人鼓舞的初步疗效，且安全性可控。
Haematologica. 2025 Feb 1;110(2):488-492. doi: 10.3324/haematol.2024.285380.
2
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.单药贝兰他单抗mafodotin 与泊马度胺联合低剂量地塞米松治疗复发或难治性多发性骨髓瘤患者的疗效和安全性（DREAMM-3）：一项开放标签、随机、3 期研究。
Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.
3
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
4
Isatuximab: A Review of Its Use in Multiple Myeloma.依沙妥昔单抗：在多发性骨髓瘤中的应用评价。
Target Oncol. 2021 Sep;16(5):675-686. doi: 10.1007/s11523-021-00827-0. Epub 2021 Aug 5.
5
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
6
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.泊马度胺联合低剂量地塞米松与高剂量地塞米松单独用于治疗复发和难治性多发性骨髓瘤（MM-003）患者：一项随机、开放标签、3 期试验。
Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
7
Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.泊马度胺单药或与地塞米松联合用于日本难治性或复发难治性多发性骨髓瘤患者。
Cancer Sci. 2015 Nov;106(11):1561-7. doi: 10.1111/cas.12772. Epub 2015 Nov 4.
8
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.英地昔单抗瑞妥昔单抗联合来那度胺或泊马度胺治疗复发/难治性多发性骨髓瘤的多中心 1/2a 期研究。
Lancet Haematol. 2021 Nov;8(11):e794-e807. doi: 10.1016/S2352-3026(21)00208-8. Epub 2021 Sep 13.
9
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.泊马度胺：复发和难治性多发性骨髓瘤的治疗药物。
Drugs. 2017 Nov;77(17):1897-1908. doi: 10.1007/s40265-017-0833-y.
10
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.帕博利珠单抗联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤患者（KEYNOTE-183）：一项随机、开放标签的3期试验。
Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
本文引用的文献
1
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.泊马度胺联合地塞米松治疗复发或难治性多发性骨髓瘤患者：非干预性研究 POSEIDON 的最终结果及其与关键性 3 期临床试验的比较。
Eur J Haematol. 2022 Feb;108(2):133-144. doi: 10.1111/ejh.13719. Epub 2021 Nov 15.
2
Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.靶向血液系统恶性肿瘤中的 CD123：确定适合靶向治疗的患者。
Leuk Lymphoma. 2021 Nov;62(11):2568-2586. doi: 10.1080/10428194.2021.1927021. Epub 2021 May 17.
3
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.解读多发性骨髓瘤临床试验数据：将研究结果转化至实际应用场景。
Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0.
4
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.针对白细胞介素-3受体的靶向疗法SL-401在母细胞样浆细胞样树突状细胞肿瘤患者中的活性。
Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23.
5
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.来那度胺单药或联合低剂量地塞米松治疗复发/难治性多发性骨髓瘤的随机 2 期研究。
Blood. 2014 Mar 20;123(12):1826-32. doi: 10.1182/blood-2013-11-538835. Epub 2014 Jan 13.
6
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.泊马度胺联合低剂量地塞米松与高剂量地塞米松单独用于治疗复发和难治性多发性骨髓瘤（MM-003）患者：一项随机、开放标签、3 期试验。
Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
7
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.高水平的 CD34+CD38low/-CD123+ blasts 可预测急性髓系白血病的不良预后：一项 Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) 研究。
Haematologica. 2011 Dec;96(12):1792-8. doi: 10.3324/haematol.2011.047894. Epub 2011 Sep 20.
8
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.白喉毒素-白细胞介素3融合蛋白在急性髓系白血病和骨髓增生异常综合征患者中的I期临床研究。
Leuk Lymphoma. 2008 Mar;49(3):543-53. doi: 10.1080/10428190701799035.
9
Metastatic cancer stem cells: a new target for anti-cancer therapy?转移性癌症干细胞：抗癌治疗的新靶点？
Cell Cycle. 2008 Jan 15;7(2):188-93. doi: 10.4161/cc.7.2.5326. Epub 2007 Nov 18.
10
Cancer stem cells.癌症干细胞。
N Engl J Med. 2006 Sep 21;355(12):1253-61. doi: 10.1056/NEJMra061808.
Zotero 插件